Format

Send to

Choose Destination
Cancers (Basel). 2018 Sep 26;10(10). pii: E356. doi: 10.3390/cancers10100356.

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.

Author information

1
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. brahimessa@med.nagoya-u.ac.jp.
2
Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. brahimessa@med.nagoya-u.ac.jp.
3
Faculty of Science, Tanta University, Tanta 31527, Egypt. brahimessa@med.nagoya-u.ac.jp.
4
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. bustositzel@med.nagoya-u.ac.jp.
5
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. t-ichinose@med.nagoya-u.ac.jp.
6
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. smatsumu@med.nagoya-u.ac.jp.
7
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. ynaoe@med.nagoya-u.ac.jp.
8
Department of Transplantation and Endocrine Surgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. miyajima@med.nagoya-u.ac.jp.
9
Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. d-morimoto@med.nagoya-u.ac.jp.
10
Department of Otolaryngology Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. tamgpad7042@gmail.com.
11
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. wu.zhiwen@med.nagoya-u.ac.jp.
12
Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. wu.zhiwen@med.nagoya-u.ac.jp.
13
Takara Bio Inc., Kusatsu, Shiga 525-0028, Japan. tanakamy@takara-bio.co.jp.
14
Office of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. hitoki@med.nagoya-u.ac.jp.
15
Office of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. sumigama@med.nagoya-u.ac.jp.
16
Office of International Affairs, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. branko@med.nagoya-u.ac.jp.
17
Department of Surgery II, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. ykodera@med.nagoya-u.ac.jp.
18
Cancer Immune Therapy Research Center, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan. kasuya@med.nagoya-u.ac.jp.

Abstract

Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene laherparepvec (T-VEC, Imlygic®) was approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for melanoma treatment in 2015. Various oncolytic viruses (OVs), such as HF10 (Canerpaturev-C-REV) and CVA21 (CAVATAK), are now actively being developed in phase II as monotherapies, or in combination with immune checkpoint inhibitors against melanoma. Moreover, in glioma, several OVs have clearly demonstrated both safety and a promising efficacy in the phase I clinical trials. Additionally, the safety of several OVs, such as pelareorep (Reolysin®), proved their safety and efficacy in combination with paclitaxel in breast cancer patients, but the outcomes of OVs as monotherapy against breast cancer have not provided a clear therapeutic strategy for OVs. The clinical trials of OVs against pancreatic cancer have not yet demonstrated efficacy as either monotherapy or as part of combination therapy. However, there are several oncolytic viruses that have successfully proved their efficacy in different preclinical models. In this review, we mainly focused on the oncolytic viruses that transitioned into clinical trials against melanoma, glioma, pancreatic, and breast cancers. Hence, we described the current status and future prospects of OVs clinical trials against melanoma, glioma, pancreatic, and breast cancers.

KEYWORDS:

breast cancer clinical trials; clinical trials; glioma; melanoma; oncolytic viruses; pancreatic

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center